I think the most obvious answer is the new hires are a means to an end. Either a large Pharma takes a
major interest in the company (with the goal of acquiring it if successful) or it is sold outright.
As they stated, they want to prevent a hostile takeover.
With all due respect (if I understand you at all) what you are suggestzing is not common in bio at all:
When an institutional investor, such as a private equity firm or a venture capitalist firm, acquires a controlling interest in a separate company. Institutional buyouts are the opposite of management buyouts (MBO), in which a business's current management acquires a large part of the company. Typically, the investor in an IBO will look to dispose of its stake in the company within a certain time frame.
Follow us: @Investopedia on Twitter
You can't be seriously speculating there will be an MBO.
Why post rubbish like that?
You are making assumptions and drawing conclusions that are not accurate.
You can have two identical trials report results on different timelines. There are many moving parts to the trials.
There are many variables inviolved in collecting and collating data from large trials like these.
I've been investing in bio a long time. I don't find it at all unusual for a high level executive to come on board without seeing the results from a 2nd phase 3 trial. They can always leave if things don't work out. In this case the odds are very good they will be successful.
I will repeat what I posted here last time. The results can not be considered late unless they are announced after company guidence. In this case that would be the second half of the 3rd quarter.
I'm as impatient as you guys but trying to guess when just makes you a little more nuts IMO.
What you are referring to is the 12 month requirement on submitting the data to the FDA for the NDA.
They can not sit on the data. The frontline results from the trial have to be publicly disclosed in a timely
The Phase 2 trial was considerably larger than most. The Phase 3 was larger than all the Linzess trials
combined. The odds are the second Phase 3 will not surprise. Large trials like these (well over 1,000 patients) are much less susesptable to error than smaller trials.
The Notice of Effectiveness means the SEC has completed its review of the most recent S-3 filing and the shares in question may now be sold. In the case of SGYP, the $250M shelf registration filed on 7/2/15 is now operational.
I actually think the mindless posting on Yahoo message boards might be a short tactic to discourage investing in particular stocks. They take over the board and many investors are psycholigally more inclined to sell.
He also emphasized the fact this is the first drug that had to prove a durable overall responder rate over the full course of the trial. He also said (what I suspected) it's impossible to compare efficacy because of the stricter guidelines Plecanatide had to use.
For all we know not only do we have a far more tolerable drug but we might very well have a more effacious drug as well.
To paraphrase : In terms of safety "boy is this a terrific drug". When people have first looked at the safety data they think "it's almost not a drug" because of how great the data looks.
Sorry if I didn't get it word for word but he made a great (if albeit short) presentation.
The outstanding tolerability of this drug is established IMO.
I don't expect a release on the 2nd phase 3 trial tomorrow.
A well done presentation with some color on the results of the recently completed Phase 3 could be enough to push this stock over 11. A statement to the effect that these are the best results of any trial of any drug in this indication to date could suffice. Something new regarding the pipeline or strategy wouldn't hurt.
That sounds very reasonable. I don't think "novice investors" could account for this type of volume on this kind of day however.
I'm going to stick to my plan to start selling when/ if it (hopefully) reaches my target price of 12. My only displine is to stick to my plan regardless of everything else if the fundamentals and technicals allow.